Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Biotest AG: Biotest AG eröffnet 9. Plasmasammelzentrum in Tschechien: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG eröffnet 9. Plasmasammelzentrum in Tschechien
DGAP-News: Biotest AG: Biotest AG eröffnet 9. Plasmasammelzentrum in Tschechien
DGAP-News: Biotest AG: Biotest AG opens ninth plasma collection centre in Czech Republic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG opens ninth plasma collection centre in Czech Republic
DGAP-News: Biotest AG: Biotest AG opens ninth plasma collection centre in Czech Republic
Chemed Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference:
Chemed Corporation to Present at the Oppenheimer 32nd Annual Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 32nd Annual Healthcare Conference on Wednesday, March 16, 2022, at approximately 8:40

Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at Oppenheimer’s 32nd Annual

DGAP-HV: Merck KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 22.04.2022 in Darmstadt (virtuelle Hauptversammlung) mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: Merck KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 22.04.2022 in Darmstadt (virtuelle Hauptversammlung) mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: Merck KGaA: Bekanntmachung der Einberufung zur Hauptversammlung am 22.04.2022 in Darmstadt (virtuelle Hauptversammlung) mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. to Present at the Barclays Global Healthcare Conference


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Tucker Kelly, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Barclays Global

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022


IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today

Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participantshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Initiates Phase 2/3 Study of Novel COVID-19 Oral Treatment in Pediatric Participants


Pfizer Inc. (NYSE: PFE) announced today that it has initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease Inhibition for COVID-19 in Pediatric Patients), to evaluate the safety

Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022


Regulatory News:



Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer will be presenting a poster with

Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022


Regulatory News:



Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq

AEVIS VICTORIA SA (AEVS:SW) announces 2021 revenues of CHF 895.9 million, up by 22.2%http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA (AEVS:SW) announces 2021 revenues of CHF 895.9 million, up by 22.2%
AEVIS VICTORIA SA (AEVS:SW) announces 2021 revenues of CHF 895.9 million, up by 22.2%
AEVIS VICTORIA SA (AEVS:SW) erzielt 2021 einen Umsatz CHF 895.9 Millionen, 22.2% über Vorjahrhttp://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA (AEVS:SW) erzielt 2021 einen Umsatz CHF 895.9 Millionen, 22.2% über Vorjahr
AEVIS VICTORIA SA (AEVS:SW) erzielt 2021 einen Umsatz CHF 895.9 Millionen, 22.2% über Vorjahr
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022: https://mms.businesswire.com/media/20191105006084/en/713581/5/Xencor_RGB_fullcolor.jpg
Xencor to Present Preclinical Data from XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022


Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will

Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital


Regulatory News:



Nanobiotix (Paris:NANO) (NASDAQ:NBTX):



Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Pfizer’s Inflammation & Immunology leadership team – Michael Gladstone, Global

Survey Shows Wide Earnings Gap Persists Between Male and Female Physicians in Maryland
Survey Shows Wide Earnings Gap Persists Between Male and Female Physicians in Maryland


A new survey indicates that wide pay gaps persist between male and female physicians in Maryland, and that Maryland physicians earn less on average than physicians nationwide.


This press release

PAVmed to Hold a Business Update Conference Call on March 29, 2022
PAVmed to Hold a Business Update Conference Call on March 29, 2022


PAVmed Inc. (Nasdaq: PAVM, PAVMZ), a highly differentiated, multi-product, commercial-stage medical device company today announced that the companies will host a business update conference call on

Simulations Plus to Present at Oppenheimer Annual Healthcare Conference: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Present at Oppenheimer Annual Healthcare Conference


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting

Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful: https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/



AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR



CSL

Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference : https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Conference


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will participate in a panel

Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022
Lucid Diagnostics to Hold a Business Update Conference Call on March 28, 2022


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 1, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit
Lucid Diagnostics to Participate in the LSI USA ’22 Emerging Medtech Summit


Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)

Valbiotis kündigt bevorstehende organisatorische Änderungen im Vorstand an: https://mms.businesswire.com/media/20200205005659/en/689755/5/valbiotis-logo.jpg
Valbiotis kündigt bevorstehende organisatorische Änderungen im Vorstand an


Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von

Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences


Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentations at two upcoming investor conferences